We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Idexx (IDXX) Down 5% Since Last Earnings Report: Can It Rebound?
Read MoreHide Full Article
It has been about a month since the last earnings report for Idexx Laboratories (IDXX - Free Report) . Shares have lost about 5% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Idexx due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
IDEXX Q4 Earnings and Revenues Top Estimates
IDEXX Laboratories posted fourth-quarter 2024 earnings per share (EPS) of $2.62, up 12.9% year over year. The figure surpassed the Zacks Consensus Estimate by 9.1%.
Comparable constant-currency EPS of $2.53 improved 10% year over year.
Full-year 2024 earnings of $10.67 rose 6.1% from the 2023 level. The figure exceeded the Zacks Consensus Estimate by 2.1%.
IDEXX’s Revenues in Detail
Quarterly revenues increased 5.8% year over year (up 6% organically) to $954.3 million. The reported figure topped the Zacks Consensus Estimate by 1.9%.
The year-over-year upside was primarily driven by Companion Animal Group ("CAG") growth of 6% as reported and organically.
Veterinary software, services and diagnostic imaging systems’ revenues increased 13% on a reported basis and 7% organically.
Full-year total revenues of $3.90 billion improved 6% on a reported basis as well as organically from the 2023 level, driven by 10% reported and 10.5% organic growth in CAG Diagnostics recurring revenues. The figure beat the Zacks Consensus Estimate by a close margin of 0.5%.
IDEXX’s Segmental Analysis
IDEXX derives revenues from four operating segments — CAG, Water, Livestock, Poultry and Dairy (“LPD”), and Other.
CAG revenues rose 6% year over year on a reported basis and on an organic basis to $870.5 million.
CAG Diagnostics’ recurring revenues also increased 6% on a reported basis and 7% organically, reflecting double-digit IDEXX VetLab consumable gains, and solid reference laboratory and consulting services growth.
The Water segment’s revenues increased 8% year over year on a reported and 9% on an organic basis to $45.2 million.
For the fourth quarter, LPD revenues increased 5% reportedly and 7% on an organic basis to $34.6 million.
Revenues from the Other segment decreased 28.6% on a reported basis to $4.1 million.
IDEXX’s Margin Performance
The gross profit rose 8.5% to $570.7 million. The gross margin expanded 144 basis points (bps) to 59.8% despite a 2.2% rise in the cost of revenues.
Sales and marketing expenses rose 5.7% to $150 million. G&A expenses surged 16.9% to $102 million. R&D expenses jumped 11.4% to $57.7 million. The operating profit in the reported quarter rose 6.4% year over year to $261.1 million. The operating margin in the quarter expanded 15 bps to 27.4%.
IDEXX’s Financial Position
IDEXX exited the fourth quarter with cash and cash equivalents of $288.3 million compared with $453.9 million at the end of 2023. Total debt (including the current portion) was $617.6 million compared with $697.9 million at the end of 2023.
The cumulative net cash provided by operating activities at the end of the fourth quarter was $929 million compared with $906.5 million in the prior-year period.
A Snapshot of IDEXX’s 2025 Guidance
IDEXX’s 2025 outlook assumes approximately 1.5 billion of share repurchases, subject to market conditions, which is equivalent to nearly 4% of current equity market capitalization.
Total revenues for 2025 are expected to be in the range of $4,055-$4,170 million, suggesting growth of 4-7% on a reported basis and 6-9% on an organic basis. The Zacks Consensus Estimate is currently pegged at $4.16 billion.
IDEXX expects full-year EPS to be in the range of $11.74-$12.24, indicating reported growth of 10-15%. The Zacks Consensus Estimate for full-year EPS is currently pegged at $11.95.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates.
The consensus estimate has shifted -5.47% due to these changes.
VGM Scores
At this time, Idexx has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. Following the exact same course, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Idexx has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Idexx (IDXX) Down 5% Since Last Earnings Report: Can It Rebound?
It has been about a month since the last earnings report for Idexx Laboratories (IDXX - Free Report) . Shares have lost about 5% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Idexx due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
IDEXX Q4 Earnings and Revenues Top Estimates
IDEXX Laboratories posted fourth-quarter 2024 earnings per share (EPS) of $2.62, up 12.9% year over year. The figure surpassed the Zacks Consensus Estimate by 9.1%.
Comparable constant-currency EPS of $2.53 improved 10% year over year.
Full-year 2024 earnings of $10.67 rose 6.1% from the 2023 level. The figure exceeded the Zacks Consensus Estimate by 2.1%.
IDEXX’s Revenues in Detail
Quarterly revenues increased 5.8% year over year (up 6% organically) to $954.3 million. The reported figure topped the Zacks Consensus Estimate by 1.9%.
The year-over-year upside was primarily driven by Companion Animal Group ("CAG") growth of 6% as reported and organically.
Veterinary software, services and diagnostic imaging systems’ revenues increased 13% on a reported basis and 7% organically.
Full-year total revenues of $3.90 billion improved 6% on a reported basis as well as organically from the 2023 level, driven by 10% reported and 10.5% organic growth in CAG Diagnostics recurring revenues. The figure beat the Zacks Consensus Estimate by a close margin of 0.5%.
IDEXX’s Segmental Analysis
IDEXX derives revenues from four operating segments — CAG, Water, Livestock, Poultry and Dairy (“LPD”), and Other.
CAG revenues rose 6% year over year on a reported basis and on an organic basis to $870.5 million.
CAG Diagnostics’ recurring revenues also increased 6% on a reported basis and 7% organically, reflecting double-digit IDEXX VetLab consumable gains, and solid reference laboratory and consulting services growth.
The Water segment’s revenues increased 8% year over year on a reported and 9% on an organic basis to $45.2 million.
For the fourth quarter, LPD revenues increased 5% reportedly and 7% on an organic basis to $34.6 million.
Revenues from the Other segment decreased 28.6% on a reported basis to $4.1 million.
IDEXX’s Margin Performance
The gross profit rose 8.5% to $570.7 million. The gross margin expanded 144 basis points (bps) to 59.8% despite a 2.2% rise in the cost of revenues.
Sales and marketing expenses rose 5.7% to $150 million. G&A expenses surged 16.9% to $102 million. R&D expenses jumped 11.4% to $57.7 million. The operating profit in the reported quarter rose 6.4% year over year to $261.1 million. The operating margin in the quarter expanded 15 bps to 27.4%.
IDEXX’s Financial Position
IDEXX exited the fourth quarter with cash and cash equivalents of $288.3 million compared with $453.9 million at the end of 2023. Total debt (including the current portion) was $617.6 million compared with $697.9 million at the end of 2023.
The cumulative net cash provided by operating activities at the end of the fourth quarter was $929 million compared with $906.5 million in the prior-year period.
A Snapshot of IDEXX’s 2025 Guidance
IDEXX’s 2025 outlook assumes approximately 1.5 billion of share repurchases, subject to market conditions, which is equivalent to nearly 4% of current equity market capitalization.
Total revenues for 2025 are expected to be in the range of $4,055-$4,170 million, suggesting growth of 4-7% on a reported basis and 6-9% on an organic basis. The Zacks Consensus Estimate is currently pegged at $4.16 billion.
IDEXX expects full-year EPS to be in the range of $11.74-$12.24, indicating reported growth of 10-15%. The Zacks Consensus Estimate for full-year EPS is currently pegged at $11.95.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates.
The consensus estimate has shifted -5.47% due to these changes.
VGM Scores
At this time, Idexx has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. Following the exact same course, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Idexx has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.